Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2023-06-05 00:00:00 ET · period of report 2023-06-01 · accession 0001714899-23-000092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-05 | 2023-06-01 | DNLI | SATO VICKI L | Dir | A - Grant | $0.00 | +4,216 | 136.4K | +3% | $0 |
| D | 2023-06-05 | 2023-06-01 | DNLI | SATO VICKI L | Dir | A - Grant | $0.00 | +12.6K | 12.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-01 | A | A | 4,216 | $0.00 | 136,369 | D | — | — | (F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. (F3) The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 9,996 shares first reflected in a Form 4 filed on 06/02/2022. (F2) Includes 4,216 unvested RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2023-06-01 | A | A | 12,649 | $0.00 | 12,649 | D | $30.92 · — to 2033-06-01 | 12,649 Common Stock | (F4) 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |